Spain's Almirall 2025 sales jump 12.4% on European dermatology business strength

Almirall

23/02/2026 06:15

Overview

Spain-based pharmaceutical firm's 2025 net sales grew 12.4%, surpassing €1 bln

EBITDA for 2025 increased 20.9% yr/yr, in line with guidance

Company's biologics portfolio, including Ilumetri and Ebglyss, drove revenue growth

Outlook

Company expects 2026 net sales growth of 9%-12%

Almirall projects 2026 EBITDA between €270 MM and €290 MM

Result Drivers

EUROPEAN DERMATOLOGY - Strong performance in European dermatology business drove 25.6% YoY sales increase to €608 MM

BIOLOGICS PORTFOLIO - Growth led by biologics portfolio with Ilumetri sales up 12.3% YoY and Ebglyss sales more than tripling

R&D INVESTMENT - Continued investment in R&D pipeline with key studies and approvals in 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
EUR 46.20 mln
FY Gross Margin
64.40%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Almirall SA is €14.00, about 4.3% above its February 20 closing price of €13.42

The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 24 three months ago

Press Release: ID:nBw5SbP1wa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)